Clinical Trials on Advanced Basal Cell Carcinoma in China

Total 2871 results

Xiang Lu

Recruiting

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell Carcinoma

China
Jacobio Pharmaceuticals Co., Ltd.
AbbVie

Recruiting

JAB-3068 Activity in Adult Patients With Advanced Solid Tumors

Non Small Cell Lung Cancer | Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Head and Neck Squamous Cell Carcinomas

China
Shandong Cancer Hospital and Institute

Recruiting

Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.

Advanced Esophageal Squamous Cell Cancer

China
Hospital of Stomatology, Wuhan University

Recruiting

The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma

Clinical IVb Stage Oral Squamous Cell Carcinomas Patients

China
Weijia Fang, MD
Akeso Pharmaceuticals, Inc.

Recruiting

Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC

China
Hutchison Medipharma Limited

Recruiting

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Advanced Renal Cell Carcinoma

China
Haihe Biopharma Co., Ltd.

Recruiting

Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33

Advanced Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Advanced Esophageal Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shenzhen Sixth People's Hospital; Zhongshan People's Hospital, Guangdong, China

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)

Head and Neck Squamous Cell Carcinomas

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
Fang Wu
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Sun Yat-sen... and other collaborators

Recruiting

ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC (CR1STAL)

Advanced Lung Non-Small Cell Carcinoma

China
Henan University of Traditional Chinese Medicine

Recruiting

Lifei Xiaoji Wan in Treatment of Advanced NSCLC

Advanced Non Small Cell Lung Cancer

China
Nanjing Tongren Hospital

Unknown

CTC Detection Rate in SCCHN With a in Vivo Device

Squamous Cell Carcinoma of the Head and Neck | Circulating Tumor Cell

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

Locally Advanced Non-small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC (InTRist)

Local Advanced Non-small Cell Lung Cancer

China
Akeso

Recruiting

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Advanced Squamous Non Small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Locally Advanced

China
Biotech Pharmaceutical Co., Ltd.

Terminated

Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

China
Guiyang Medical University

Unknown

the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer

Locally Advanced Head and Neck Squamous Cell Carcinoma

China
Sun Yat-sen University

Unknown

Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy

Advanced Cancer | Small Cell Carcinoma of Esophagus

China
Huazhong University of Science and Technology

Not yet recruiting

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Advanced or Metastatic EP-NEC

China
Xinqiao Hospital of Chongqing

Completed

Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01)

Advanced Nsclc

China
Allist Pharmaceuticals, Inc.

Unknown

AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Advanced NSCLC

China
Guangzhou Gloria Biosciences Co., Ltd.

Not yet recruiting

Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Advanced Non-Small-Cell Lung Cancer

China
Peking Union Medical College Hospital

Recruiting

Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)

Advanced Non-small Cell Lung Cancer

China
Akeso

Active, not recruiting

AK112 in Advanced Non-Small Cell Lung Cancer

Advanced Non-small-cell Lung Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Advanced Non-small Cell Lung Cancer

China
Shandong Simcere-Medgenn Bio-pharmaceutical Co....

Completed

Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Jiesi Yingda Pharmaceutical Technology (Suzhou)...

Recruiting

VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer (VIC-1911)

Advanced Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Fudan University

Unknown

Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer

Local Advanced Non-Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
Affiliated Cancer Hospital & Institute of Guangzhou...

Recruiting

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Advanced Non-Small Cell Lung Cancer

China
Yongchang Zhang

Completed

Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Suzhou Junjing BioSciences Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer

Locally Advanced or Metastatic NSCLC

China
Allist Pharmaceuticals, Inc.

Unknown

Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Advanced NSCLC Patients With T790M

China
Shanghai Henlius Biotech

Active, not recruiting

HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Squamous-cell Non-small Cell Lung Cancer

China
The Fourth Affiliated Hospital of Zhejiang University...
Second Affiliated Hospital, School of Medicine, Zhejiang University

Recruiting

Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Fifth Affiliated Hospital, Sun Yat-Sen University

Completed

Brain Metabolic Network of PET in Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non-small-cell Lung Cancer

China
Haihua Yang

Unknown

Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Recruiting

Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer

Untreated Advanced Non-small Cell Lung Cancer

China
The First Affiliated Hospital of Xiamen University

Recruiting

A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy

Advanced Non-Small Cell Lung Cancer

China
suhaichuan
Shanghai Biomed-union Biotechnology Co., Ltd.

Recruiting

Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC)

Chemotherapy | Advanced Non-small Cell Lung Cancer

China
Sun Yat-sen University

Completed

Study of Early Nutritional Intervention During Concurrent Chemoradiotherapy for Local Advanced Non-small Cell Lung Cancer

Local Advanced Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Enrolling by invitation

Tislelizumab as Cross-line Treatment for Advanced NSCLC

Advanced Non-small-cell Lung Cancer

China
Sun Yat-sen University

Unknown

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc (NSCLC EGFR TKI)

Advanced Stage Non Small Cell Lung Cancer

China
Xinqiao Hospital of Chongqing

Withdrawn

Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients (XQonc-007)

Advanced Non-squamous Non-small-cell Lung Cancer

China
Xinqiao Hospital of Chongqing

Withdrawn

Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen

Advanced Non-squamous Non-small-cell Lung Cancer

China

3

Subscribe